Ftse Mib
34.660,38
-0,50%
DAX
18.557,27
-0,48%
S&P 500
5.346,99
-0,11%
NASDAQ
17.133,13
-0,23%
Bitcoin
69.233,01
-0,11%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Agenus Inc (AGEN) Agenus Inc (AGEN) Notizie

Agenus Inc

AGEN
16,20
-0,36 (-2,17%)
08 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
04/6/202413:30BWAgenus Announces Virtual Annual Shareholders Meeting
30/5/202422:01EDGAR2Form 8-K - Current report
24/5/202423:00BWAgenus Reports Inducement Grants Under Nasdaq Listing Rule..
23/5/202423:10BWBreakthrough Data on Botensilimab/Balstilimab in MSS CRC..
23/5/202413:30BWAgenus to Participate in Goldman Sachs 45th Annual Global..
16/5/202413:30BWFDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss..
07/5/202413:40BWAgenus Reports First Quarter 2024 Results
07/5/202413:39EDGAR2Form 8-K - Current report
07/5/202413:38EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202413:31EDGAR2Form 8-K - Current report
01/5/202413:30BWAgenus Regains Compliance with Nasdaq Minimum Bid Price..
24/4/202416:00BWBotensilimab/Balstilimab Data in MSS CRC Selected for the..
23/4/202413:30BWAgenus to Provide First Quarter 2024 Financial Report and..
12/4/202413:30BWAgenus Announces Updated Phase 1 Data and Progress on..
05/4/202422:30BWAgenus Announces Reverse Stock Split of Common Stock
14/3/202412:30BWAgenus Reports Fourth Quarter and Full Year 2023 Results
06/3/202413:30BWAgenus Announces Preclinical Data on BMS-986442 (AGEN1777)..
05/3/202422:30BWAgenus Reports Inducement Grants Under Nasdaq Listing Rule..
29/2/202422:50EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29/2/202413:30BWAgenus to Provide Corporate Update and Fourth Quarter & Full..
26/2/202422:24EDGAR2Form DEF 14A - Other definitive proxy statements
26/2/202413:30BWAgenus to Participate in Leerink Partners Global Biopharma..
15/2/202414:02EDGAR2Form PRE 14A - Other preliminary proxy statements
15/2/202414:00EDGAR2Form 8-K - Current report
15/2/202413:02PRNUSGinkgo Bioworks and SaponiQx Awarded MCDC Contract to..
14/2/202414:33EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202413:00EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
09/2/202423:11EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/1/202414:00EDGAR2Form 8-K - Current report
31/1/202413:30BWAgenus to Participate in Oppenheimer 34th Annual Healthcare..
22/1/202415:59BWBotensilimab/Balstilimab Breakthrough Data Presented at..
22/1/202413:30BWBotensilimab/Balstilimab Breakthrough Data Presented at..
05/1/202422:30BWAgenus Reports Inducement Grants Under Nasdaq Listing Rule..
04/1/202413:30BWAgenus to Participate in B. Riley Healthcare Conference
04/1/202412:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202412:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202412:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202313:30BWBotensilimab/Balstilimab Data in Neoadjuvant Colorectal..
11/12/202313:30BWAgenus to Receive $25 Million Milestone Payment from Bristol..
08/12/202322:15EDGAR2Form 8-K - Current report
17/11/202322:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202312:30EDGAR2Form 8-K - Current report
07/11/202312:30BWAgenus Reports Third Quarter 2023 Results
26/10/202315:05BWAgenus to Provide Third Quarter 2023 Financial Report and..
22/10/202318:00BWAgenus Unveils New and Updated Botensilimab Data in..
21/10/202310:15BWESMO 2023: Agenus’ Botensilimab/Balstilimab Combination..
16/10/202323:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/10/202313:30BWAgenus Completes Enrollment in Randomized Phase 2 Clinical..
06/10/202322:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 16,45 Min: 15,80 Max: 16,7309
Chiusura: 16,56

La tua Cronologia

NASDAQ
AGEN
Agenus
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network